| NCT ID | NCT06068257 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Central Florida |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 210 participants |
| Start Date | 2023-06-06 |
| Primary Completion | 2025-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 210 participants in total. It began in 2023-06-06 with a primary completion date of 2025-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Identify and test thresholds, specificity and sensitivity for a potential cancer associated biomarker protein, FGF19, (and associated markers) for detection in human blood in the blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls
Eligibility Criteria
Inclusion Criteria: * The study will enroll adult persons with breast cancer or colorectal cancer or no cancer (healthy controls) who are able to do a fasting blood draw. (Pregnant women may choose to be in the study. The study procedures do not pose a risk to the safety of the unborn child or the woman.) Exclusion Criteria: * The study will not enroll persons who are unable or unwilling to provide informed consent. * Adults unable to consent, individuals who are not yet adults, and prisoners will be excluded from this study.
Contact & Investigator
Deborah Altomare, PhD
PRINCIPAL INVESTIGATOR
University of Central Florida College of Medicine
Frequently Asked Questions
Who can join the NCT06068257 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06068257 currently recruiting?
Yes, NCT06068257 is actively recruiting participants. Contact the research team at amoy.fraser@ucf.edu for enrollment information.
Where is the NCT06068257 trial being conducted?
This trial is being conducted at Orlando, United States.
Who is sponsoring the NCT06068257 clinical trial?
NCT06068257 is sponsored by University of Central Florida. The principal investigator is Deborah Altomare, PhD at University of Central Florida College of Medicine. The trial plans to enroll 210 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.